Health Catalyst Competitors

TripAdvisor (NASDAQ:TRIP) and Health Catalyst (NASDAQ:HCAT) are both mid-cap retail/wholesale companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of recent ratings and target prices for TripAdvisor and Health Catalyst, as provided by MarketBeat.

TripAdvisor presently has a consensus target price of $38.1579, indicating a potential downside of 18.66%. Health Catalyst has a consensus target price of $45.1429, indicating a potential downside of 10.86%. Given Health Catalyst's stronger consensus rating and higher possible upside, analysts plainly believe Health Catalyst is more favorable than TripAdvisor.

Insider and Institutional Ownership

69.5% of TripAdvisor shares are owned by institutional investors. Comparatively, 94.2% of Health Catalyst shares are owned by institutional investors. 3.5% of TripAdvisor shares are owned by insiders. Comparatively, 22.1% of Health Catalyst shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

TripAdvisor has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Earnings and Valuation

This table compares TripAdvisor and Health Catalyst's revenue, earnings per share (EPS) and valuation.

TripAdvisor has higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than TripAdvisor, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TripAdvisor and Health Catalyst's net margins, return on equity and return on assets.

Summary

Health Catalyst beats TripAdvisor on 8 of the 15 factors compared between the two stocks.

OneConnect Financial Technology (NYSE:OCFT) and Health Catalyst (NASDAQ:HCAT) are both mid-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Insider and Institutional Ownership

14.4% of OneConnect Financial Technology shares are owned by institutional investors. Comparatively, 94.2% of Health Catalyst shares are owned by institutional investors. 22.1% of Health Catalyst shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for OneConnect Financial Technology and Health Catalyst, as reported by MarketBeat.

OneConnect Financial Technology presently has a consensus price target of $26.80, suggesting a potential upside of 81.82%. Health Catalyst has a consensus price target of $45.1429, suggesting a potential downside of 10.86%. Given OneConnect Financial Technology's higher possible upside, analysts clearly believe OneConnect Financial Technology is more favorable than Health Catalyst.

Valuation & Earnings

This table compares OneConnect Financial Technology and Health Catalyst's top-line revenue, earnings per share and valuation.

Health Catalyst has lower revenue, but higher earnings than OneConnect Financial Technology. Health Catalyst is trading at a lower price-to-earnings ratio than OneConnect Financial Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OneConnect Financial Technology and Health Catalyst's net margins, return on equity and return on assets.

Dada Nexus (NASDAQ:DADA) and Health Catalyst (NASDAQ:HCAT) are both mid-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Dada Nexus and Health Catalyst, as reported by MarketBeat.com.

Dada Nexus presently has a consensus target price of $41.00, suggesting a potential upside of 82.87%. Health Catalyst has a consensus target price of $45.1429, suggesting a potential downside of 10.86%. Given Dada Nexus' higher probable upside, equities analysts clearly believe Dada Nexus is more favorable than Health Catalyst.

Earnings and Valuation

This table compares Dada Nexus and Health Catalyst's revenue, earnings per share (EPS) and valuation.

Health Catalyst has lower revenue, but higher earnings than Dada Nexus. Health Catalyst is trading at a lower price-to-earnings ratio than Dada Nexus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dada Nexus and Health Catalyst's net margins, return on equity and return on assets.

Institutional & Insider Ownership

15.3% of Dada Nexus shares are held by institutional investors. Comparatively, 94.2% of Health Catalyst shares are held by institutional investors. 22.1% of Health Catalyst shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Health Catalyst beats Dada Nexus on 8 of the 14 factors compared between the two stocks.

Chindata Group (NASDAQ:CD) and Health Catalyst (NASDAQ:HCAT) are both mid-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Earnings and Valuation

This table compares Chindata Group and Health Catalyst's top-line revenue, earnings per share (EPS) and valuation.

Chindata Group has higher earnings, but lower revenue than Health Catalyst.

Profitability

This table compares Chindata Group and Health Catalyst's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Chindata Group and Health Catalyst, as provided by MarketBeat.com.

Chindata Group presently has a consensus target price of $20.91, indicating a potential upside of 49.04%. Health Catalyst has a consensus target price of $45.1429, indicating a potential downside of 10.86%. Given Chindata Group's higher possible upside, research analysts plainly believe Chindata Group is more favorable than Health Catalyst.

Institutional and Insider Ownership

18.9% of Chindata Group shares are owned by institutional investors. Comparatively, 94.2% of Health Catalyst shares are owned by institutional investors. 22.1% of Health Catalyst shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rackspace Technology (NASDAQ:RXT) and Health Catalyst (NASDAQ:HCAT) are both mid-cap business services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Rackspace Technology and Health Catalyst's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Rackspace Technology and Health Catalyst's revenue, earnings per share and valuation.

Rackspace Technology has higher earnings, but lower revenue than Health Catalyst.

Insider and Institutional Ownership

78.3% of Rackspace Technology shares are held by institutional investors. Comparatively, 94.2% of Health Catalyst shares are held by institutional investors. 22.1% of Health Catalyst shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Rackspace Technology and Health Catalyst, as provided by MarketBeat.com.

Rackspace Technology presently has a consensus price target of $27.9545, indicating a potential upside of 11.82%. Health Catalyst has a consensus price target of $45.1429, indicating a potential downside of 10.86%. Given Rackspace Technology's higher probable upside, analysts clearly believe Rackspace Technology is more favorable than Health Catalyst.

Health Catalyst (NASDAQ:HCAT) and Sabre (NASDAQ:SABR) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Analyst Recommendations

This is a summary of recent ratings and target prices for Health Catalyst and Sabre, as reported by MarketBeat.

Health Catalyst presently has a consensus target price of $45.1429, suggesting a potential downside of 10.86%. Sabre has a consensus target price of $13.60, suggesting a potential downside of 5.42%. Given Sabre's higher possible upside, analysts clearly believe Sabre is more favorable than Health Catalyst.

Insider and Institutional Ownership

94.2% of Health Catalyst shares are owned by institutional investors. Comparatively, 96.2% of Sabre shares are owned by institutional investors. 22.1% of Health Catalyst shares are owned by insiders. Comparatively, 0.7% of Sabre shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Health Catalyst and Sabre's net margins, return on equity and return on assets.

Risk and Volatility

Health Catalyst has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Sabre has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.

Earnings and Valuation

This table compares Health Catalyst and Sabre's top-line revenue, earnings per share and valuation.

Sabre has higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than Sabre, indicating that it is currently the more affordable of the two stocks.

Summary

Sabre beats Health Catalyst on 8 of the 15 factors compared between the two stocks.